Blog

Extracorporeal Membrane Oxygenation Machine Market Size, Emergi

• Publicado por ivar kings 29 de setembro de 2023 - Arquivado em Saúde - #Extracorporeal Membrane Oxygenation Machine Market  #ECMO Machine market  - 19 visualizações

   

  Extracorporeal Membrane Oxygenation (ECMO) Machine

  An extracorporeal membrane oxygenation (ECMO) machine is a device that helps to improve oxygen levels in the blood and remove carbon dioxide. The global extracorporeal membrane oxygenation machine market is expected to grow from USD 283.07 million in 2022 to USD 393.64 million by 2028 at a healthy CAGR of 5.60% during the forecast period.

  It is used when a person's heart and lungs are unable to work properly. ECMO is a life-saving therapy that can be used to treat a variety of conditions, including:

  • Acute respiratory distress syndrome (ARDS)
  • Severe pneumonia
  • Heart failure
  • Cardiogenic shock
  • Congenital heart defects
  • Meconium aspiration syndrome
  • Sepsis

  The ECMO machine works by taking blood from the body and pumping it through a membrane oxygenator. The oxygenator adds oxygen to the blood and removes carbon dioxide. The blood is then warmed and returned to the body.

  Market Dynamics

  The key factors driving the market growth include:

  • Increasing prevalence of respiratory and cardiovascular disorders worldwide
  • Growing demand for ECMO therapy from both newborns and adults
  • Expanding aging population, which is highly susceptible to chronic medical ailments

  Key Players

  The following are the key players operating in the global extracorporeal membrane oxygenation machine market:

  • Terumo (Japan)
  • Medtronic (Ireland)
  • Getinge (Sweden)
  • LivaNova (UK)
  • Nipro (Japan)
  • MicroPort (China)
  • XENIOS (Germany)
  • OriGen (US)

  Regional Insight

  North America accounted for the highest share of more than 35% in 2022 and is expected to grow at a robust CAGR during the review period. The market growth in North America is attributed to the large presence of key players, a growing number of product launches, high purchasing power parity, surging government support for quality healthcare, and increasing prevalence of chronic obstructive pulmonary disease.

  Asia Pacific is expected to grow at a healthy CAGR during the review period due to a surge in healthcare expenditure by the government as well as private agencies to improve healthcare facilities. Increasing government initiatives related to the development of healthcare infrastructure & reimbursement policies further bolsters the regional market growth.